X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds for funding clinical trials and nonclinical studies of the Company’s product candidates, including, FT576, an investigational, off-the-shelf CAR NK cell cancer immunotherapy derived from a clonal master iPSC line.
Lead Product(s): FT576
Therapeutic Area: Oncology Product Name: FT576
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 19, 2024
Details:
ONO-8250 (FT825) is a multiplexed-engineered, chimeric antigen receptor (CAR) T-cell product candidate targeting human epidermal growth factor receptor 2 (HER2). It is under phase 1 clinical development for the treatment of HER2-expressing Advanced Solid Tumors.
Lead Product(s): FT825
Therapeutic Area: Oncology Product Name: ONO-8250
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
FT576 (CAR NK cells) is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line. FT576 incorporates a proprietary CAR that targets BCMA, a novel high-affinity 158V and non-cleavable CD16 (hnCD16) Fc receptor.
Lead Product(s): Allogenic CAR NK Cell,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: FT576
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Janssen
Deal Size: $3,100.0 million Upfront Cash: $100.0 million
Deal Type: Termination January 05, 2023
Details:
FT819 is an investigational, universal, off-the-shelf, T-cell receptor (TCR)-less CD19 chimeric antigen receptor (CAR) T-cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line.
Lead Product(s): FT819,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: FT819
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2022
Details:
Under the terms of the Collaboration and Option Agreement, the parties will jointly develop and commercialize FT825 (ONO-8250) in the U.S. and Europe, and ONO maintains exclusive development and commercialization rights for FT825 (ONO-8250) in the rest of the world.
Lead Product(s): ONO-8250
Therapeutic Area: Oncology Product Name: FT825
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 07, 2022
Details:
FT819, an off-the-shelf CAR T-cell cancer immunotherapy derived from a clonal engineered master iPSC line with a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus and edited for elimination of T-cell receptor (TCR) expression.
Lead Product(s): FT819
Therapeutic Area: Oncology Product Name: FT819
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Preclinical data to be presented demonstrate that iPSC-derived, MICA/B-targeted CAR NK cells induced potent activity against AML cell line HL60, and further enhancement of activity was achieved in combination with GTB-3650 through antibody-dependent cellular cytotoxicity.
Lead Product(s): GTB-3650,CAR NK Cell Therapy
Therapeutic Area: Oncology Product Name: GTB-3650
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: GT Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
FT536 is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master engineered iPSC line. FT536 incorporates a proprietary CAR that targets the α3 domain of MICA and MICB.
Lead Product(s): FT536,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: FT536
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
With this agreement, the discovery of iPSC-derived CAR-NK cell therapy will be added to iPSC-derived CAR-T cells therapy for solid tumors. And, a second new target for solid tumor collaboration has been added and ONO will provide Fate with antibodies that bind to the target.
Lead Product(s): IPSC-derived CAR NK Cell Therapy,IPSC-derived CAR T-Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration June 28, 2022
Details:
FT536 also incorporates a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; an IL-15 receptor fusion (IL-15RF) that augments NK cell activity.
Lead Product(s): FT536
Therapeutic Area: Oncology Product Name: FT536
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
